Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
10 mai 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
10 mai 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
Highlights: Continued expansion of ATH434 Phase 2 Clinical Trial with sites open for recruitment in five countriesParticipants in the US and Europe received first dose as part of the ATH434 Phase 2...
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
26 avr. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 26, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
04 avr. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
16 mars 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
14 mars 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’s – – Newly patented compounds and legacy asset PBT2 licensed...
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
16 févr. 2023 16h44 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...